Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where D Followill is active.

Publication


Featured researches published by D Followill.


Medical Physics | 2010

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict; Kamil M. Yenice; D Followill; James M. Galvin; William H. Hinson; Brian D. Kavanagh; P Keall; Michael Lovelock; Sanford L. Meeks; Lech Papiez; Thomas G. Purdie; R Sadagopan; Michael C. Schell; Bill J. Salter; David Schlesinger; Almon S. Shiu; Timothy D. Solberg; Danny Y. Song; Volker W. Stieber; Robert D. Timmerman; Wolfgang A. Tomé; Dirk Verellen; Lu Wang; Fang-Fang Yin

Task Group 101 of the AAPM has prepared this report for medical physicists, clinicians, and therapists in order to outline the best practice guidelines for the external-beam radiation therapy technique referred to as stereotactic body radiation therapy (SBRT). The task group report includes a review of the literature to identify reported clinical findings and expected outcomes for this treatment modality. Information is provided for establishing a SBRT program, including protocols, equipment, resources, and QA procedures. Additionally, suggestions for developing consistent documentation for prescribing, reporting, and recording SBRT treatment delivery is provided.


International Journal of Radiation Oncology Biology Physics | 1997

Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy

D Followill; Paul Geis; Arthur L. Boyer

PURPOSE To estimate the dose delivered to patients by photons and neutrons outside the radiation fields when beam intensity modulation conformal radiotherapy is given. These estimates are then used to compute the risk of secondary cancers as a sequela of the radiation therapy. MATERIALS AND METHODS The x-ray and neutron leakage accompanying two beam-intensity modulation techniques delivered by currently available linear accelerators were estimated for 6-MV, 18-MV, and 25-MV x-ray energies. Estimates of whole-body dose equivalents were determined using leakage measurements reported in the literature and treatment parameters derived for two modulated beam-intensity conformal therapy techniques. Risk values recommended by the National Council on Radiation Protection and Measurements (NCRP) were used to estimate the resulting risk of fatal radiation-induced cancer for 70.00 Gy prescribed tumor doses. RESULTS The computed worst-case risks of secondary cancers increased in the range from 1.00% for 6-MV x-rays to 24.4% for 25-MV x-rays. CONCLUSIONS Careful consideration should be made of the risks associated with secondary whole-body radiation before implementation of beam intensity modulated conformal therapy at x-ray energies greater than 10 MV.


International Journal of Radiation Oncology Biology Physics | 2003

The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas

Subir Nag; Jeanne M. Quivey; John D. Earle; D Followill; James Fontanesi; Paul T. Finger

PURPOSE This article presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with choroidal melanomas. METHODS Members of the ABS with expertise in choroidal melanoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. RESULTS Episcleral plaque brachytherapy is a complex procedure and should only be undertaken in specialized medical centers with expertise in this sophisticated treatment program. Recommendations were made for patient selection, techniques, dose rates, and dosages. Most patients with very small uveal melanomas (<2.5 mm height and <10 mm in largest basal dimension) should be observed for tumor growth before treatment. Patients with a clinical diagnosis of medium-sized choroidal melanoma (between 2.5 and 10 mm in height and <16 mm basal diameter) are candidates for episcleral plaques if the patient is otherwise healthy and without metastatic disease. A histopathologic verification is not required. Small melanomas may be candidates if there is documented growth; some patients with large melanomas (>10 mm height or >16 mm basal diameter) may also be candidates. Patients with large tumors or with tumors at peripapillary and macular locations have a poorer visual outcome and lower local control that must be taken into account in the patient decision-making process. Patients with gross extrascleral extension, ring melanoma, and tumor involvement of more than half of the ciliary body are not suitable for plaque therapy. For plaque fabrication, the ophthalmologist must provide the tumor size (including basal diameters and tumor height) and a detailed fundus diagram. The ABS recommends a minimum tumor (125)I dose of 85 Gy at a dose rate of 0.60-1.05 Gy/h using AAPM TG-43 formalism for the calculation of dose. NRC or state licensing guidelines regarding procedures for handling of radioisotopes must be followed. CONCLUSIONS Brachytherapy represents an effective means of treating patients with choroidal melanomas. Guidelines are established for the use of brachytherapy in the treatment of choroidal melanomas. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose reporting policies. These guidelines will be modified as further clinical results become available.


Medical Physics | 2010

QA for helical tomotherapy: Report of the AAPM Task Group 148

Katja M. Langen; N Papanikolaou; John Balog; Richard J. Crilly; D Followill; S. Murty Goddu; Walter Grant; Gustavo H. Olivera; C Ramsey; Chengyu Shi

Helical tomotherapy is a relatively new modality with integrated treatment planning and delivery hardware for radiation therapy treatments. In view of the uniqueness of the hardware design of the helical tomotherapy unit and its implications in routine quality assurance, the Therapy Physics Committee of the American Association of Physicists in Medicine commissioned Task Group 148 to review this modality and make recommendations for quality assurance related methodologies. The specific objectives of this Task Group are: (a) To discuss quality assurance techniques, frequencies, and tolerances and (b) discuss dosimetric verification techniques applicable to this unit. This report summarizes the findings of the Task Group and aims to provide the practicing clinical medical physicist with the insight into the technology that is necessary to establish an independent and comprehensive quality assurance program for a helical tomotherapy unit. The emphasis of the report is to describe the rationale for the proposed QA program and to provide example tests that can be performed, drawing from the collective experience of the task group members and the published literature. It is expected that as technology continues to evolve, so will the test procedures that may be used in the future to perform comprehensive quality assurance for helical tomotherapy units.


Practical radiation oncology | 2011

RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1-3) spine metastases: Phase 2 results

Samuel Ryu; Stephanie L. Pugh; Peter C. Gerszten; Fang-Fang Yin; Robert D. Timmerman; Ying J. Hitchcock; Benjamin Movsas; Andrew A. Kanner; Lawrence Berk; D Followill; Lisa A. Kachnic

PURPOSE The phase 2 component of Radiation Therapy Oncology Group (RTOG) 0631 assessed the feasibility and safety of spine radiosurgery (SRS) for localized spine metastases in a cooperative group setting. METHODS AND MATERIALS Patients with 1-3 spine metastasis with a Numerical Rating Pain Scale (NRPS) score ≥5 received 16 Gy single fraction SRS. The primary endpoint was SRS feasibility: image guidance radiation therapy (IGRT) targeting accuracy ≤2 mm, target volume coverage >90% of prescription dose, maintaining spinal cord dose constraints (10 Gy to ≤10% of the cord volume from 5-6 mm above to 5-6 mm below the target or absolute spinal cord volume <0.35 cc) and other normal tissue dose constraints. A feasibility success rate <70% was considered unacceptable for continuation of the phase 3 component. Based on the 1-sample exact binomial test with α = 0.10 (1-sided), 41 patients were required. Acute toxicity was assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3.0. RESULTS Sixty-five institutions were credentialed with spine phantom dosimetry and IGRT compliance. Forty-six patients were accrued, and 44 were eligible. There were 4 cervical, 21 thoracic, and 19 lumbar sites. Median NRPS was 7 at presentation. Final pretreatment rapid review was approved in 100%. Accuracy of image guided SRS targeting was in compliance with the protocol in 95%. The target coverage and spinal cord dose constraint were in accordance with the protocol requirements in 100% and 97%. Overall compliance for other normal tissue constraints was per protocol in 74%. There were no cases of grade 4-5 acute treatment-related toxicity. CONCLUSIONS The phase 2 results demonstrate the feasibility and accurate use of SRS to treat spinal metastases, with rigorous quality control, in a cooperative group setting. The planned RTOG 0631 phase 3 component will proceed to compare pain relief and quality of life between SRS and external beam radiation therapy.


Medical Physics | 2014

Addendum to the AAPM's TG-51 protocol for clinical reference dosimetry of high-energy photon beams

M McEwen; Larry A. DeWerd; Geoffrey S. Ibbott; D Followill; D. W. O. Rogers; Stephen M. Seltzer; J Seuntjens

An addendum to the AAPMs TG-51 protocol for the determination of absorbed dose to water in megavoltage photon beams is presented. This addendum continues the procedure laid out in TG-51 but new kQ data for photon beams, based on Monte Carlo simulations, are presented and recommendations are given to improve the accuracy and consistency of the protocols implementation. The components of the uncertainty budget in determining absorbed dose to water at the reference point are introduced and the magnitude of each component discussed. Finally, the consistency of experimental determination of ND,w coefficients is discussed. It is expected that the implementation of this addendum will be straightforward, assuming that the user is already familiar with TG-51. The changes introduced by this report are generally minor, although new recommendations could result in procedural changes for individual users. It is expected that the effort on the medical physicists part to implement this addendum will not be significant and could be done as part of the annual linac calibration.


Journal of Applied Clinical Medical Physics | 2003

Neutron source strength measurements for Varian, Siemens, Elekta, and General Electric linear accelerators

D Followill; Marilyn S. Stovall; Stephen F. Kry; Geoffrey S. Ibbott

The shielding calculations for high energy (> 10 MV) linear accelerators must include the photoneutron production within the head of the accelerator. Procedures have been described to calculate the treatment room door shielding based on the neutron source strength (Q value) for a specific accelerator and energy combination. Unfortunately, there is currently little data in the literature stating the neutron source strengths for the most widely used linear accelerators. In this study, the neutron fluence for 36 linear accelerators, including models from Varian, Siemens, Elekta/Philips, and General Electric, was measured using gold‐foil activation. Several of the models and energy combinations had multiple measurements. The neutron fluence measured in the patient plane was independent of the surface area of the room, suggesting that neutron fluence is more dependent on the direct neutron fluence from the head of the accelerator than from room scatter. Neutron source strength, Q, was determined from the measured neutron fluences. As expected, Q increased with increasing photon energy. The Q values ranged from 0.02 for a 10 MV beam to 1.44(×1012) neutrons per photon Gy for a 25 MV beam. The most comprehensive set of neutron source strength values, Q, for the current accelerators in clinical use are presented for use in calculating room shielding. PACS number(s): 87.53.–j, 87.52.–g


Medical Physics | 2007

Design, development, and implementation of the Radiological Physics Center’s pelvis and thorax anthropomorphic quality assurance phantoms

D Followill; Dee Ann Radford Evans; Christopher P. D. Cherry; A Molineu; Gary Fisher; William F. Hanson; Geoffrey S. Ibbott

The Radiological Physics Center (RPC) developed two heterogeneous anthropomorphic quality assurance phantoms for use in verifying the accuracy of radiation delivery: one for intensity-modulated radiation therapy (IMRT) to the pelvis and the other for stereotactic body radiation therapy (SBRT) to the thorax. The purpose of this study was to describe the design and development of these two phantoms and to demonstrate the reproducibility of measurements generated with them. The phantoms were built to simulate actual patient anatomy. They are lightweight and water-fillable, and they contain imageable targets and organs at risk of radiation exposure that are of similar densities to their human counterparts. Dosimetry inserts accommodate radiochromic film for relative dosimetry and thermoluminesent dosimetry capsules for absolute dosimetry. As a part of the commissioning process, each phantom was imaged, treatment plans were developed, and radiation was delivered at least three times. Under these controlled irradiation conditions, the reproducibility of dose delivery to the target TLD in the pelvis and thorax phantoms was 3% and 0.5%, respectively. The reproducibility of radiation-field localization was less than 2.5 mm for both phantoms. Using these anthropomorphic phantoms, pelvic IMRT and thoracic SBRT radiation treatments can be verified with a high level of precision. These phantoms can be used to effectively credential institutions for participation in specific NCI-sponsored clinical trials.


Medical Physics | 2006

A Monte Carlo model for calculating out-of-field dose from a Varian 6 MV beam

Stephen F. Kry; U Titt; Falk Pönisch; D Followill; Oleg N. Vassiliev; R. Allen White; Radhe Mohan; Mohammad Salehpour

Dose to the patient outside of the treatment field is important when evaluating the outcome of radiotherapy treatments. However, determining out-of-field doses for any particular treatment plan currently requires either time-consuming measurements or calculated estimations that may be highly uncertain. A Monte Carlo model may allow these doses to be determined quickly, accurately, and with a great degree of flexibility. MCNPX was used to create a Monte Carlo model of a Varian Clinac 2100 accelerator head operated at 6MV. Simulations of the dose out-of-field were made and measurements were taken with thermoluminescent dosimeters in an acrylic phantom and with an ion chamber in a water tank to validate the Monte Carlo model. Although local differences between the out-of-field doses calculated by the model and those measured did exceed 50% at some points far from the treatment field, the average local difference was only 16%. This included a range of doses as low as 0.01% of the central axis dose, and at distances in excess of 50cm from the central axis of the treatment field. The out-of-field dose was found to vary with field size and distance from the central axis, but was almost independent of the depth in the phantom except where the dose increased substantially at depths less than dmax. The relationship between dose and kerma was also investigated, and kerma was found to be a good estimate of dose (within 3% on average) except near the surface and in the field penumbra. Our Monte Carlo model was found to well represent typical Varian 2100 accelerators operated at 6MV.


Medical Physics | 2009

Recommendations for clinical electron beam dosimetry: Supplement to the recommendations of Task Group 25

Bruce J. Gerbi; John A. Antolak; F. Christopher Deibel; D Followill; Michael G. Herman; P Higgins; M. Saiful Huq; D Mihailidis; Ellen Yorke; Kenneth R. Hogstrom; Faiz M. Khan

The goal of Task Group 25 (TG-25) of the Radiation Therapy Committee of the American Association of.Physicists in Medicine (AAPM) was to provide a methodology and set of procedures for a medical physicist performing clinical electron beam dosimetry in the nominal energy range of 5-25 MeV. Specifically, the task group recommended procedures for acquiring basic information required for acceptance testing and treatment planning of new accelerators with therapeutic electron beams. Since the publication of the TG-25 report, significant advances have taken place in the field of electron beam dosimetry, the most significant being that primary standards laboratories around the world have shifted from calibration standards based on exposure or air kerma to standards based on absorbed dose to water. The AAPM has published a new calibration protocol, TG-51, for the calibration of high-energy photon and electron beams. The formalism and dosimetry procedures recommended in this protocol are based on the absorbed dose to water calibration coefficient of an ionization chamber at 60Co energy, N60Co(D,w), together with the theoretical beam quality conversion coefficient k(Q) for the determination of absorbed dose to water in high-energy photon and electron beams. Task Group 70 was charged to reassess and update the recommendations in TG-25 to bring them into alignment with report TG-51 and to recommend new methodologies and procedures that would allow the practicing medical physicist to initiate and continue a high quality program in clinical electron beam dosimetry. This TG-70 report is a supplement to the TG-25 report and enhances the TG-25 report by including new topics and topics that were not covered in depth in the TG-25 report. These topics include procedures for obtaining data to commission a treatment planning computer, determining dose in irregularly shaped electron fields, and commissioning of sophisticated special procedures using high-energy electron beams. The use of radiochromic film for electrons is addressed, and radiographic film that is no longer available has been replaced by film that is available. Realistic stopping-power data are incorporated when appropriate along with enhanced tables of electron fluence data. A larger list of clinical applications of electron beams is included in the full TG-70 report available at http://www.aapm.org/pubs/reports. Descriptions of the techniques in the clinical sections are not exhaustive but do describe key elements of the procedures and how to initiate these programs in the clinic. There have been no major changes since the TG-25 report relating to flatness and symmetry, surface dose, use of thermoluminescent dosimeters or diodes, virtual source position designation, air gap corrections, oblique incidence, or corrections for inhomogeneities. Thus these topics are not addressed in the TG-70 report.

Collaboration


Dive into the D Followill's collaboration.

Top Co-Authors

Avatar

Stephen F. Kry

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Geoffrey S. Ibbott

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

A Molineu

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

P Alvarez

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Rebecca M. Howell

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

P Balter

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J Lowenstein

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

L Court

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

N Hernandez

University of Texas MD Anderson Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge